211 related articles for article (PubMed ID: 16636685)
1. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations.
Nakajima M; Fukami T; Yamanaka H; Higashi E; Sakai H; Yoshida R; Kwon JT; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2006 Sep; 80(3):282-97. PubMed ID: 16952495
[TBL] [Abstract][Full Text] [Related]
3. Novel human CYP2A6 alleles confound gene deletion analysis.
Nakajima M; Yoshida R; Fukami T; McLeod HL; Yokoi T
FEBS Lett; 2004 Jul; 569(1-3):75-81. PubMed ID: 15225612
[TBL] [Abstract][Full Text] [Related]
4. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
5. A novel duplication type of CYP2A6 gene in African-American population.
Fukami T; Nakajima M; Yamanaka H; Fukushima Y; McLeod HL; Yokoi T
Drug Metab Dispos; 2007 Apr; 35(4):515-20. PubMed ID: 17267622
[TBL] [Abstract][Full Text] [Related]
6. A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo.
Fukami T; Nakajima M; Yoshida R; Tsuchiya Y; Fujiki Y; Katoh M; McLeod HL; Yokoi T
Clin Pharmacol Ther; 2004 Dec; 76(6):519-27. PubMed ID: 15592323
[TBL] [Abstract][Full Text] [Related]
7. Nicotine metabolism and CYP2A6 allele frequencies in Koreans.
Kwon JT; Nakajima M; Chai S; Yom YK; Kim HK; Yamazaki H; Sohn DR; Yamamoto T; Kuroiwa Y; Yokoi T
Pharmacogenetics; 2001 Jun; 11(4):317-23. PubMed ID: 11434509
[TBL] [Abstract][Full Text] [Related]
8. Structural characterization of a new variant of the CYP2A6 gene (CYP2A6*1B) apparently diagnosed as heterozygotes of CYP2A6*1A and CYP2A6*4C.
Ariyoshi N; Takahashi Y; Miyamoto M; Umetsu Y; Daigo S; Tateishi T; Kobayashi S; Mizorogi Y; Loriot MA; Stücker I; Beaune P; Kinoshita M; Kamataki T
Pharmacogenetics; 2000 Nov; 10(8):687-93. PubMed ID: 11186131
[TBL] [Abstract][Full Text] [Related]
9. CYP2A6 and CYP2E1 polymorphisms in a Brazilian population living in Rio de Janeiro.
Rossini A; Lima SS; Rapozo DC; Faria M; Albano RM; Pinto LF
Braz J Med Biol Res; 2006 Feb; 39(2):195-201. PubMed ID: 16470306
[TBL] [Abstract][Full Text] [Related]
10. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype.
Nunoya K; Yokoi T; Takahashi Y; Kimura K; Kinoshita M; Kamataki T
J Biochem; 1999 Aug; 126(2):402-7. PubMed ID: 10423536
[TBL] [Abstract][Full Text] [Related]
11. Comparison of cytochrome P450 2A6 polymorphism frequencies in Caucasians and African-Americans using a new one-step PCR-RFLP genotyping method.
Paschke T; Riefler M; Schuler-Metz A; Wolz L; Scherer G; McBride CM; Bepler G
Toxicology; 2001 Nov; 168(3):259-68. PubMed ID: 11684323
[TBL] [Abstract][Full Text] [Related]
12. Genetic polymorphisms in human CYP2A6 gene causing impaired nicotine metabolism.
Yoshida R; Nakajima M; Watanabe Y; Kwon JT; Yokoi T
Br J Clin Pharmacol; 2002 Nov; 54(5):511-7. PubMed ID: 12445030
[TBL] [Abstract][Full Text] [Related]
13. Relationship between interindividual differences in nicotine metabolism and CYP2A6 genetic polymorphism in humans.
Nakajima M; Kwon JT; Tanaka N; Zenta T; Yamamoto Y; Yamamoto H; Yamazaki H; Yamamoto T; Kuroiwa Y; Yokoi T
Clin Pharmacol Ther; 2001 Jan; 69(1):72-8. PubMed ID: 11180041
[TBL] [Abstract][Full Text] [Related]
14. Identification of novel CYP2A6*1B variants: the CYP2A6*1B allele is associated with faster in vivo nicotine metabolism.
Mwenifumbo JC; Lessov-Schlaggar CN; Zhou Q; Krasnow RE; Swan GE; Benowitz NL; Tyndale RF
Clin Pharmacol Ther; 2008 Jan; 83(1):115-21. PubMed ID: 17522595
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of cytochrome P450 2A6*1A alleles in a black African population of Ghana.
Gyamfi MA; Fujieda M; Kiyotani K; Yamazaki H; Kamataki T
Eur J Clin Pharmacol; 2005 Feb; 60(12):855-7. PubMed ID: 15660270
[TBL] [Abstract][Full Text] [Related]
16. Characterisation and PCR-based detection of a CYP2A6 gene deletion found at a high frequency in a Chinese population.
Oscarson M; McLellan RA; Gullstén H; Yue QY; Lang MA; Bernal ML; Sinues B; Hirvonen A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Apr; 448(1):105-10. PubMed ID: 10217419
[TBL] [Abstract][Full Text] [Related]
17. Ethnic variation in CYP2A6*7, CYP2A6*8 and CYP2A6*10 as assessed with a novel haplotyping method.
Mwenifumbo JC; Myers MG; Wall TL; Lin SK; Sellers EM; Tyndale RF
Pharmacogenet Genomics; 2005 Mar; 15(3):189-92. PubMed ID: 15861044
[TBL] [Abstract][Full Text] [Related]
18. New CYP2A6 gene deletion and conversion variants in a population of Black African descent.
Mwenifumbo JC; Zhou Q; Benowitz NL; Sellers EM; Tyndale RF
Pharmacogenomics; 2010 Feb; 11(2):189-98. PubMed ID: 20136358
[TBL] [Abstract][Full Text] [Related]
19. Three haplotypes associated with CYP2A6 phenotypes in Caucasians.
Haberl M; Anwald B; Klein K; Weil R; Fuss C; Gepdiremen A; Zanger UM; Meyer UA; Wojnowski L
Pharmacogenet Genomics; 2005 Sep; 15(9):609-24. PubMed ID: 16041240
[TBL] [Abstract][Full Text] [Related]
20. Identification and characterisation of novel polymorphisms in the CYP2A locus: implications for nicotine metabolism.
Oscarson M; McLellan RA; Gullstén H; Agúndez JA; Benítez J; Rautio A; Raunio H; Pelkonen O; Ingelman-Sundberg M
FEBS Lett; 1999 Oct; 460(2):321-7. PubMed ID: 10544257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
